Companies › TriSalus Life Sciences
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SD-101 TLR9 agonist | TLR9 | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma; Hepatocellular Carcinoma | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05607953 | SD-101 | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Oncology | Sep 2027 |
| NCT06710223 | SD-101 | Phase 1 | Hepatocellular Carcinoma | Oncology | Dec 2027 |
Cash of $41m on 2026-09-30; operating cash outflow about $29m a year; runway about 17 months at that burn, to Feb 2028
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.